Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-03-27, Stock:LLY, The news for the past five days is as follows:
2018-03-20: NEWS1: Roche Tecentriq Phase III Combo Study Meets Primary Endpoint.NEWS2: Roche Tecentriq Phase III Combo Study Meets Primary Endpoint.NEWS3: CVS appoints former Eli Lilly CFO as president of PBM business.NEWS4: Understanding Nektar Therapeutics’ Top-Line Performance.NEWS5: CVS to Hire Former Eli Lilly CFO to Run Pharmacy Benefit Business.NEWS6: 3 High-Quality Dividend-Payers Selling at a Discount.
2018-03-21: NEWS1: After Hours Most Active for Mar 21, 2018 :  LC, HPE, OAS, BAC, LLY, RRC.NEWS2: After Hours Most Active for Mar 21, 2018 :  LC, HPE, OAS, BAC, LLY, RRC.NEWS3: Ignore Trump's Pricing Rhetoric With These 5 Biotech Picks.NEWS4: Ignore Trump's Pricing Rhetoric With These 5 Biotech Picks.NEWS5: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS6: A Look at Nektar Therapeutics’ Cash Flows.NEWS7: CVS to Hire Former Eli Lilly CFO to Run Pharmacy Benefit Business.
2018-03-22: NEWS1: Merck Gets European Committee Vote for Veterinary Product.NEWS2: Merck Gets European Committee Vote for Veterinary Product.NEWS3: Waltham’s Radius Health says osteoporosis drug rejected in Europe.NEWS4: Eli Lilly: Is the Coast Now Clear for the Bulls?.NEWS5: See what the IHS Markit Score report has to say about Eli Lilly And Co..
2018-03-23: NEWS1: Radius Health Down on Negative CHMP Opinion for Lead Drug.NEWS2: Radius Health Down on Negative CHMP Opinion for Lead Drug.NEWS3: Incyte’s Product Portfolio in March 2018.NEWS4: Incyte’s Revenue Stream in 4Q17.NEWS5: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS6: Incyte’s Revenue Trends in 4Q17.
2018-03-26: NEWS1: Roche's Tecentriq Combo Study Meets Co-Primary Endpoint.NEWS2: Roche's Tecentriq Combo Study Meets Co-Primary Endpoint.NEWS3: Top Analyst Reports for Nike, Eli Lilly & NVIDIA.NEWS4: Top Analyst Reports for Nike, Eli Lilly & NVIDIA.NEWS5: Top Analyst Reports for Nike, Eli Lilly & NVIDIA.NEWS6: Here's Why Biohaven Pharmaceutical Holding Co Ltd's Getting Hammered Today.NEWS7: Here's Why Biohaven Pharmaceutical Holding Co Ltd's Getting Hammered Today.NEWS8: Here&apos;s Why Biohaven Pharmaceutical Holding Co Ltd&apos;s Getting Hammered Today.NEWS9: Pfizer's Chantix Fails in Phase IV Study in Young Smokers.NEWS10: Pfizer's Chantix Fails in Phase IV Study in Young Smokers.NEWS11: Analysts’ Recommendations for Incyte in March 2018.NEWS12: Pfizer&apos;s Chantix Fails in Phase IV Study in Young Smokers.NEWS13: Will Teva’s Fremanezumab Be Delayed due to Troubles at Celltrion?.NEWS14: Incyte’s Collaborations and Developments in 2018.NEWS15: See what the IHS Markit Score report has to say about Eli Lilly And Co..

Answer: Decrease